Quoin Pharmaceuticals, Ltd.
QNRXHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Quoin Pharmaceuticals, Ltd. focuses on Biotechnology services and products. Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. Valued at $14.4M, QNRX is a micro-cap name in its sector. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.
Market Cap
$14.4M
Beta
1.73
P/E (TTM)
—
P/E (Fwd)
-2.24
EPS (TTM)
$-5.67
EPS (Fwd)
$-3.19
ROE
-575.7%
ROA
-114.6%
Cash
$10.8M
Total Debt
$2.0M
Free CF
-$8.0M
52W Change
-2.0%
Annual Financials
Cash vs Debt
Where QNRX stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, QNRX finished 7.96% above its 150-day moving average ($6.03) and 19.23% below its 200-day moving average ($8.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is QNRX overbought or oversold?
At the September 2, 2026 close, QNRX's RSI(14) was 56.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $10.8M in cash comfortably exceeding the $2.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$8.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -575.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, QNRX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, QNRX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing QNRX.